Used in scans for disrupted blood brain barrier and/or abnormal vascularity in the brain (intracranial lesions). Sold as Prohance, Prohance Multipack. Every FDA application for this active ingredient: 2 branded and 1 generic.
As of Nov 16, 2026, FDA lists 3 applications for Gadoteridol (sold as Prohance, Prohance Multipack), first approved Nov 16, 1992, with 4 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Prohance Multipack | Part B | $283K | -31% | 12,924 |
| Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple SclerosisMultiple Sclerosis · Sanofi | Phase 2 | Active, not recruiting | May 10, 2021 |
| Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI)Triple Negative Breast Cancer · University of Alabama at Birmingham | Early phase 1 | Recruiting | Apr 27, 2021 |
| Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 YearsMotor Function, Cognitive Function · Guerbet | Phase 4 | Recruiting | May 4, 2020 |
| Nov 16, 1992 | ProhanceNDA 20131 · New molecular entity | Bracco | 28 | Marketed |
| Oct 9, 2003 | Prohance MultipackNDA 21489 · New dosage form | Bracco | 14 | Marketed |
| Feb 11, 2025 | GadoteridolANDA 218749 | Hainan Poly | 1 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA